Literature DB >> 10456621

Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation.

A Ascani1, A Iorio, G Agnelli.   

Abstract

The optimal procedure for withdrawal of warfarin in patients with deep vein thrombosis (DVT) is still not defined. Rebound thrombin generation, which occurs after the withdrawal of warfarin, has been said to be associated with early recurrence of DVT. The aim of this study was to compare two procedures for warfarin withdrawal after the first episode of DVT with respect to rebound thrombin generation. Forty-one consecutive patients were randomly assigned to abrupt withdrawal of warfarin (group A), or to an additional month of warfarin, at the fixed dose of 1.25 mg/day (group B). Plasma samples were withdrawn for the assay of prothrombin fragment F1+2 (F1+2), protein C, factor VII and International Normalized Ratio (INR), before any anticoagulant treatment (I), during initial heparin (II) and full dose warfarin (III), at the end of full dose warfarin (IV) and then 1 (V), 4 (VI), 5 (VII) and 9 (VIII) weeks after randomization. The mean duration of full-dose warfarin treatment, the mean warfarin dose and the mean INR during full-dose warfarin treatment were similar in the two groups. A decrease in F1+2 was observed during heparin and warfarin treatment (II, 1.7 nmol/ml; III, 1.0 nmol/ml; IV, 0.7 nmol/ml; versus I, 3.5 nmol/ml; P<0.01). After the withdrawal of warfarin, an increase in F1+2 was observed in both groups, but without significant statistical differences (group A: V, 1.2 nmol/ml; VI, 1.5 nmol/ml; VII, 1.6 nmol/ml; VIII, 1.1 nmol/ml; group B: V, 1.3 nmol/ml; IV, 1.5 nmol/ml; VII, 1.4 nmol/ml; VIII, 1.4 nmol/ml). No significant difference between the two groups was observed in the recovery of protein C and factor VII. Four patients experienced a recurrence of DVT, three in group B and one in group A. Our findings confirm that rebound thrombin generation occurs in patients with DVT after the withdrawal of warfarin. Rebound thrombin generation is not reduced by a low, fixed dose of warfarin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456621

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  7 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Thromboembolism.

Authors:  Richard J McManus; David A Fitzmaurice; Ellen Murray; Clare Taylor
Journal:  BMJ Clin Evid       Date:  2011-03-08

3.  Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism.

Authors:  David Keith Cundiff
Journal:  Medscape J Med       Date:  2008-11-11

4.  Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.

Authors:  Xiaoxi Yao; Neena S Abraham; G Caleb Alexander; William Crown; Victor M Montori; Lindsey R Sangaralingham; Bernard J Gersh; Nilay D Shah; Peter A Noseworthy
Journal:  J Am Heart Assoc       Date:  2016-02-23       Impact factor: 5.501

5.  Current practice and effects of intravenous anticoagulant therapy in hospitalized acute heart failure patients with sinus rhythm.

Authors:  Hiroki Nakano; Yasuhiro Hamatani; Toshiyuki Nagai; Michikazu Nakai; Kunihiro Nishimura; Yoko Sumita; Hisao Ogawa; Toshihisa Anzai
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 6.  Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.

Authors:  Saskia Middeldorp; Martin H Prins; Barbara A Hutten
Journal:  Cochrane Database Syst Rev       Date:  2014-08-05

Review 7.  Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions.

Authors:  Eveline T Engelen; Roger Eg Schutgens; Evelien P Mauser-Bunschoten; Robert Jj van Es; Karin Pm van Galen
Journal:  Cochrane Database Syst Rev       Date:  2018-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.